Story perspectives

Thermo Fisher sells microbiology unit to Astorg for $1.1 B.

4/28/2026

Summary

Thermo Fisher Sells

Thermo Fisher Scientific agreed to sell its microbiology business to Astorg for US$1.075 billion plus a US$50 million seller note.
The unit earned US$645 million in 2025, employed 2,400 staff and operated 13 sites worldwide.
The transaction will create an independent Astorg-backed platform, dilute Thermo Fisher’s EPS by US$0.15 in the first full year, and is expected to close in the second half of 2026 pending approvals.

Summary

Thermo Fisher Warns

Thermo Fisher Scientific reports adjusted earnings per share that exclude transaction costs, restructuring charges and acquisition amortization.
The company says non-GAAP metrics give investors a clearer view of core operating performance.
It cannot issue forward-looking GAAP numbers because the timing of restructuring, acquisition charges and legal outcomes is uncertain.
The release warns the microbiology business sale may be delayed, face regulatory hurdles, incur costs or be terminated.

1 of 2

Thermo Fisher Sells

Thermo Fisher Scientific agreed to sell its microbiology business to Astorg for US$1.075 billion plus a US$50 million seller note.
The unit earned US$645 million in 2025, employed 2,400 staff and operated 13 sites worldwide.
The transaction will create an independent Astorg-backed platform, dilute Thermo Fisher’s EPS by US$0.15 in the first full year, and is expected to close in the second half of 2026 pending approvals.

1 / 2